Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.
Deucravacitinib was approved for medical use in the United States in September 2022, and in Australia in December 2022. The US Food and Drug Administration considers it to be a first-in-class medication. From Wikipedia
